Altogether, these findings strongly suggest that MXD3 is an oncogenic molecule of tumor progression, various tumor stages, and metastasis, and hence could serve as early biomarker for cancer detection, staging, and follow-up. This evidence concerns the gene MXD3 and neoplasm.